Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study

Majumder, Khairul; Nilsson, Sten; Johansson, Hemming; Ullén, Anders; Lennernäs, Bo; Bergenmar, Mia; Brandberg, Yvonne

doi:10.1016/j.ejca.2016.06.011

Cited by 2 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been presented in patients treated with pelvic irradiation, both men and women, where defecation urgency and faecal leakage has been identified as the most disturbing of all radiation-induced symptoms (17)(18)(19)(20)(21). In the neoadjuvant study (12), differences between the groups at the three months' assessment, before the start of RT, were found for 'overall quality of life', 'fatigue' and 'sexual interest', all in favour of monotherapy. These differences were expected, as castration obtained in Group B might cause these problems.…”

Section: Discussionsupporting

confidence: 76%

“…A total of 110 patients were included in the neoadjuvant study (12). Eleven patients were, however, not included in the present analyses as information of PV at baseline was lacking.…”

Section: Resultsmentioning

confidence: 99%

“…Consecutive patients with localised prostate cancer intended for curative treatment with radiotherapy were included in the randomised ADT study (12). The primary aim of the ADT study was to compare health-related quality-of-life (HRQoL) between the two groups over time.…”

Section: Methodsmentioning

confidence: 99%

“…In addition, a PV evaluation in ten patients before prostate brachytherapy showed that the CT-based prostate volumes ranged from 31.1 cubic centimetres (cc) to 48.1 cc, whereas corresponding figures for transrectally ultrasound (TRUS)-based volumes were 26.6 to 46.4 cc (10 There is, to our knowledge, no published randomised study addressing differences in PV reduction following treatment with an androgen receptor inhibitor monotherapy vs castration plus an androgen receptor inhibitor. Thus, the aim of the present study was to compare changes in PV in the randomised ADT study (12). The hypothesis was that PV reduction would be larger in the combined group compared to androgen receptor inhibitor monotherapy, and that PTV subsequently would be smaller in the castration plus androgen receptor inhibitor group.…”

Section: Introductionmentioning

confidence: 97%

“…Between 2005 and 2011 a total of 110 patients were included in the ADT study (12). Before 2008, the referring urologist measured PV (Volume 1) before referral to the Department of Oncology.…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract. To avoid pubic arch interference, prostate cancer patients are treated with neoadjuvant androgen deprivation therapy (ADT) to achieve prostate volume (PV) reduction prior to radiation treatment. The aim of the present randomised study was to compare the effects on PV of two regimens of ADT, an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. Consecutive patients with non-metastatic prostate cancer were included in a randomised neoadjuvant study, comparing an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. PV was assessed prior to the start of endocrine neoadjuvant treatment and prior to the start of radiation therapy (RT). PV assessment was performed by transrectal ultrasound. A total of 110 patients were included. Final sample constituted 88 (80%) patients due to lack of PV information. Castration plus an androgen receptor inhibitor was more effective in PV reduction compared with an androgen receptor inhibitor alone (P<0.001). Planning target volume decreased in the combination arm. There was no significant difference in clinical or demographic or length of neoadjuvant hormonal treatment between the groups. Overall, a significantly larger PV reduction was achieved by castration plus androgen receptor inhibitor, as compared with androgen receptor inhibitor monotherapy. The PV reduction, however, appeared not to translate into better health associated quality of life during the subsequently given curative intended combined EBRT and HDR-brachytherapy. Potential differences between these two treatments regarding anti-tumor effects on micro metastatic disease and radiation potentiating effect remains to be addressed in future prospective trials.

show abstract

Section: Discussionsupporting

confidence: 76%

“…A total of 110 patients were included in the neoadjuvant study (12). Eleven patients were, however, not included in the present analyses as information of PV at baseline was lacking.…”

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations